The Committee shall:
- Gather and disseminate information to further the public's understanding of metabolic disorders;
- Consult the public, especially committees and groups of persons particularly affected by metabolic disorder programs;
- Make available to the public information on the operation of all programs on metabolic disorders within the District of Columbia, except for confidential information;
- Reevaluate on a continuing basis the need for and efficacy of newborn screening tests for galactosemia, homocystinuria, hypothyroidism, maple syrup urine disease, PKU, and sickle hemoglobinopathy;
- Recommend to the Mayor any additional screening tests for metabolic disorders that should be added to those required under § 7-833(a);
- Recommend to the Mayor any screening tests for metabolic disorders required under § 7-833(a) that should be deleted;
- Consider the incidence of each metabolic disorder and the cost of detection and management of each metabolic disorder, and, where appropriate, consult District of Columbia and national experts concerning the medical, psychological, ethical, social and economic effects of programs for the detection and management of metabolic disorders;
- Keep the Mayor informed as to new and improved techniques for screening and testing newborns for metabolic disorders; and
- Recommend to the Mayor a laboratory or laboratories for designation under § 7-833(b).
Historical and Statutory
1981 Ed., § 6-316.
Legislative History of Laws
For legislative history of D.C. Law 3-65, see Historical and Statutory Notes following § 7-831.
For legislative history of D.C. Law 6-13, see Historical and Statutory Notes following § 7-832.
DC CODE § 7-836
Current through December 11, 2012
(Apr. 29, 1980, D.C. Law 3-65, § 7, 27 DCR 1087; July 25, 1985, D.C. Law 6-13, § 2(c), 32 DCR 3235.)